$3.10
0.32% yesterday
NYSE, Aug 21, 10:00 pm CET
ISIN
CH0499880968
Symbol
ADCT

Adc Therapeutics SA Stock price

$3.10
-0.04 1.27% 1M
+1.47 90.18% 6M
+1.11 55.78% YTD
+0.16 5.44% 1Y
-4.36 58.45% 3Y
-39.42 92.71% 5Y
-26.55 89.54% 10Y
-26.55 89.54% 20Y
NYSE, Closing price Thu, Aug 21 2025
-0.01 0.32%
ISIN
CH0499880968
Symbol
ADCT
Industry

Key metrics

Basic
Market capitalization
$349.9m
Enterprise Value
$533.0m
Net debt
$183.2m
Cash
$264.6m
Shares outstanding
112.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.5 | 4.4
EV/Sales
6.9 | 6.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-62.9%
Return on Equity
77.9%
ROCE
-49.6%
ROIC
-348.3%
Debt/Equity
-2.2
Financials (TTM | estimate)
Revenue
$77.3m | $79.2m
EBITDA
$-125.2m | $-169.3m
EBIT
$-127.5m | $-143.9m
Net Income
$-169.9m | $-144.1m
Free Cash Flow
$-128.8m
Growth (TTM | estimate)
Revenue
-35.4% | 11.7%
EBITDA
52.6% | -32.9%
EBIT
52.0% | -10.2%
Net Income
54.2% | 8.7%
Free Cash Flow
11.5%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
-162.1% | -213.9%
EBIT
-165.1%
Net
-220.0% | -182.1%
Free Cash Flow
-166.8%
More
EPS
$-1.5
FCF per Share
$-1.1
Short interest
6.2%
Employees
264
Rev per Employee
$270.0k
Show more

Is Adc Therapeutics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Adc Therapeutics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Adc Therapeutics SA forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Adc Therapeutics SA forecast:

Buy
92%
Hold
8%

Financial data from Adc Therapeutics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
77 77
35% 35%
100%
- Direct Costs 5.12 5.12
23% 23%
7%
72 72
36% 36%
93%
- Selling and Administrative Expenses 81 81
53% 53%
105%
- Research and Development Expense 119 119
42% 42%
154%
-125 -125
53% 53%
-162%
- Depreciation and Amortization 2.30 2.30
52% 52%
3%
EBIT (Operating Income) EBIT -128 -128
52% 52%
-165%
Net Profit -170 -170
54% 54%
-220%

In millions USD.

Don't miss a Thing! We will send you all news about Adc Therapeutics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adc Therapeutics SA Stock News

Neutral
Seeking Alpha
9 days ago
ADC Therapeutics SA (NYSE:ADCT ) Q2 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Ameet Mallik - CEO & Director Jose I. Carmona - Chief Financial Officer Mohamed Zaki - Chief Medical Officer Nicole Riley - Corporate Participant Conference Call Participants Eric Thomas Schmidt - Cantor Fitzgerald & Co., Research Division Jenna Li - Jefferies LLC, Research Division...
Neutral
PRNewsWire
10 days ago
ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in LOTIS-7 across 30 efficacy evaluable patients Expansion to 100 r/r DLBCL patients underway in LOTIS-7 Phase 1b trial; Additional data to be shared in second half of 2025 LOTIS-5 Phase 3 trial expected to reach prespecified progression-free survival ...
Neutral
PRNewsWire
16 days ago
LAUSANNE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates.
More Adc Therapeutics SA News

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Head office Switzerland
CEO Ameet Mallik
Employees 264
Founded 2011
Website adctherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today